Indeed, CD19‐293‐EV treatment induces the downregulation of CD19, p‐AKT, and MYC, indicating that, like CD19‐293, CD19‐293‐EVs also trigger B‐ALL target cell death via disruption of the CD19/AKT/MYC axis (Figure S4, Supporting Information). Here, AKT1 is linked to acute lymphoblastic leukemia.